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BIOMEDICAL RESEARCH AND THE LAWEMBRYONIC STEM CELLS,
CLONES, AND GENES:
SCIENCE, LAW, POLITICS, AND VALUES
FOREWORD
Janet L. Dolgin *
Joel Weintraub**
The articles presented in this symposium issue developed from
papers delivered at the second in a series of conferences at Hofstra
University devoted to the study of "Biomedical Research and the Law."
The first conference, held in October 2006,' focused on conflicts
occasioned by industry funding of biomedical research. The second

conference, the subject of this issue, occurred in March 2008 and was
dedicated to the study of "Embryonic Stem Cells, Clones, and Genes:
Science, Law, Politics and Values." 2 This conference provided a

*

Jack and Freda Dicker Distinguished Professor of Health Care Law, Hofstra Law School.

B.A. (philosophy), Barnard College; M.A., Ph.D. (anthropology), Princeton University; J.D., Yale
Law School.
** Special Professor of Law, Hofstra Law School. A.B., Columbia College; M.D., College of
Physicians and Surgeons of Columbia University; J.D., Hofstra Law School.
1. Papers delivered at the first conference in the series, "The Pharmaceutical Industry and Its
Relationship with Government, Academia, Physicians, and Consumers," are included in a
symposium issue of the Hofstra Law Review. Symposium, Biomedical Research and the LawSelected Issues: The PharmaceuticalIndustry and Its Relationship with Government, Academia,
Physicians, and Consumers, 35 HOFSTRA L. REv. 681 (2006). The symposium volume includes
papers delivered at that conference.
2. We are grateful to Hofstra University, Hofstra Law School, the Hofstra Cultural Center,
and the law firm of Garfunkel, Wild & Travis, P.C. for supporting and sponsoring the conference.
We are especially appreciative to Natalie Datlof, Executive Director, and Athelene A. Collins,
Senior Associate Director, both of the Hofstra Cultural Center. Their commitment to the project
contributed significantly to its success. We appreciate the participation of North Shore-Long Island
Jewish Health System in planning the conference. We thank Toni Aiello, Reference Librarian at
Hofstra Law School, for generous and intelligent help in identifying research material, and we thank
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productive context for debate among lawyers, physicians, scientists,
theologians, philosophers, journalists, and others about a set of pressing
questions facing American society. Among these were questions about
how, if at all, to regulate research involving the destruction of embryos,
about how best to fund such research, about the potential medical uses of
human embryonic stem cells, and about the likely social consequences
of research involving them. Participants in the conference debated the
relationship between science and religion, and the significance to be
assigned to each in research involving embryonic stem cells.
The papers presented at the second conference discussed the moral
and political contexts of the intense debate regarding human embryonic
stem cell ("hESC") research and developments in science that may
diminish the intensity of the debate, or render it moot. Those matters are
discussed in the four articles included in this symposium issue, and other
related matters are expounded. These articles are significant not only in
and of themselves, but also because, considered together, they animate
the contours of a comprehensive debate about America as a culture. The
debate between opponents and proponents of hESC research on moral
grounds is sharply focused and fervent.
Pro-life adherents typically argue, on religious grounds, that the
destruction of embryos is the destruction of human life.3 Other
opponents of hESC research would limit or preclude the research
because, they argue, it links commerce to "desperation" in the search for
medical cures, or because it threatens to "redefin[e]" human nature.4 Still
others urge caution regarding hESC research because, they suspect,
absent more stringent regulation than now exists, securing ova for
research may harm the women from whom the ova are obtained.5

Maggie Emma, J.D. candidate 2010, Hofstra Law School, and Fellow in the Institute for Health
Law and Policy at Hofstra Law School, for research assistance.
3. Erin P. George, Comment, The Stem Cell Debate: The Legal, Political and Ethical Issues
Surrounding Federal Funding of Scientific Research on Human Embryos, 12 ALB. L.J. Sci. &
TECH. 747, 782-84 (2002); see also Paul Lauritzen, Dir., Applied Ethics Program, John Carroll
Univ., Session 2: Stem Cell Research: Current Ethical Literature, Address Before the President's
Council
on
Bioethics
(July
24,
2003),
available at http://www.bioethics.gov/
transcripts/july03/session2.htm (noting the fervency of the opposition to stem cell research by prolife advocates).
4. See Lauritzen, supra note 3.
5. See id.
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Proponents of increased support for hESC research appeal primarily
to its medical promise: 6 to the hope it prompts for the relief of suffering
and pain and even for the cure of a wide variety of diseases.7
The debate about hESC research in the United States has also
centered on federal funding. 8 In August 2001, President George W. Bush
precluded the use of federal funds for almost all research on embryonic
stem cell lines. 9 President Bush's 2001 "compromise" decision remained
in effect until March 2009, when the executive policy was radically
altered by a contravening Executive Order issued by President Barack
Obama.10 On March 9, 2009, President Obama provided that "[t]he
Secretary of Health and Human Services[,] .. . through the Director of
NIH, may support and conduct responsible, scientifically worthy human
stem cell research, including human embryonic stem cell research, to the
extent permitted by law.""
More generally, the debate about hESCs may diminish in intensity
and significance, or perhaps even be rendered moot, by ongoing
experiments with a variety of stem cell types that may obviate the need
for embryos in stem cell research. Research alternatives include the use
of adult stem cells, as well as the use of induced pluripotent stem cells
12
("iPSCs")-pluripotent stem cells derived from adult skin cells.
Scientists hope that iPSCs may preclude the need for research on human

6. See, e.g., Michelle L. Anderson, Comment, Are You My Mommy? A Callfor Regulation of
Embryo Donation, 35 CAP. U. L. REv. 589, 620 (2006); George, supra note 3, at 770, 791-93
(describing the promise of stem cell research as "staggering").
7. Proponents also point to variations among major religions of the concept of the sanctity of
the early human embryo. See, e.g., HossAM E. FADEL ET AL., ISLAMIC MED. ASS'N OF N. AM.,
STEM CELL RESEARCH:
THE IMANA PERSPECTIVE
8-11,
http://www.imana.org/
PDF%20Files/Stem%2OCell%2OPosition.pdf (last visited Apr. 15, 2009).
8. George, supra note 3, at 782, 790-93; see also John A. Robertson, Embryo Culture and
the "Culture of Life": Constitutional Issues in the Embryonic Stem Cell Debate, 2006 U. CHI.
LEGAL F. 1, 2-3. Robertson suggests that funding restrictions, such as the one imposed by George
W. Bush, limited stem cell research by "prevent[ing] the National Institutes of Health ("NIH") from
playing its traditional role of supporting research that is too far upstream from marketable products
to attract private investment." Robertson, supra, at 2.
9. Press Release, George W. Bush, Remarks on Stem Cell Research (Aug. 9, 2001),
available at http://georgewbush-whitehouse.archives.gov/news/releases/2001/08/20010809-2.html.
Bush provided that federal funds could be used only for hESC research on lines created before
August 9, 2001, the date of his address. Id. He explained that research on pre-existing lines was
permissible because "the life and death decision has been already made." Id.
10. Exec. Order No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009).
11. Id. The practical consequences of the words "to the extent permitted by law" are still not
known. We are grateful to Professor Alan Jakimo for his insights on this issue.
12. See Gina Kolata, Scientists Bypass Needfor Embryo to Get Stem Cells, N.Y. TIMES, Nov.
21, 2007, at Al.

Published by Scholarly Commons at Hofstra Law, 2008

3

Hofstra Law Review, Vol. 37, Iss. 2 [2008], Art. 1
HOFSTRA LA W REVIEW

[Vol. 37:313

embryos.13 However, others suggest that hESCs are likely to offer a safer
treatment option than iPSCs. 14 Thus, at present, many experts maintain
5
that traditional embryonic stem cell research should be continued..
Each of the articles in this symposium issue suggests an essential
dimension of the scientific or socio-legal consequences of the debate
regarding hESC research. One religious perspective, among several
represented at the conference, is reflected in the article by Dr. Gerard
Magill, who offers a Catholic argument based on the "development of
doctrine" that would allow Catholics to support hESC research. 16 Owen
C.B. Hughes, Alan L. Jakimo, and Michael J. Malinowski, the authors of
United States Regulation of Stem Cell Research: Recasting
Government's Role and Questions to Be Resolved, focus on conflicts
between federal and state law about how to regulate stem cell research
and stem cell medicine.17 These conflicts, they argue, have been a
consequence of the inability of the NIH to take a leading regulatory role
in this area of health science.' 8 Hughes, Jakimo, and Malinowski focus,
in particular, on conflicts between the federal system for licensing
patents and the system in California.' 9 Perhaps some of the conflicts
outlined in their article can be resolved in light of President Obama's
March 9, 2009 Order that permits federal funding for "human embryonic
stem cell research, to the extent permitted by law.",20 Dr. Samuel
Packer's article, Embryonic Stem Cells, Intellectual Property, and
Patents: Ethical Concerns, constructs a comprehensive ethical
framework for furthering deliberation about the ethics of embryonic

13. Id.
14. Colin Nickerson, Caution Urgedin New Methodfor Stem Cells, BOSTON GLOBE, Dec. 17,
2007, at Al.
15. George, supra note 3, at 796-98.
16. Gerard Magill, Using Excess IVF Blastocysts for Embryonic Stem Cell Research:
Developing Ethical Doctrine, Secularand Religious, 37 HOFsrRA L. REV. 447, 453-54 (2009).
17. See generally Owen C.B. Hughes et al., United States Regulation of Stem Cell Research:
Recasting Government's Role and Questions to Be Resolved, 37 HOFsTRA L. REV. 383 (2009)
(comparing federal intellectual property law with the Californian model for stem cell research
regulation and encouragement).
18. Seeid at403-19.
19. Id. at 423-45. The authors note that a number of other states have programs for funding
stem cell research. However, they have focused on California because its funding program is "the
most ambitious state effort to fill a science funding vacuum created through federal government law
and policy." Id. at 385.
20. Exec. Order No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009). As noted above, the extent
to which such resolution is possible depends on interpretations of the language "to the extent
permitted by law" in the Executive Order. Id.
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stem cell research and medicine. 21 In developing that framework,
Dr. Packer considers social values and beliefs as well as various
perspectives about science, knowledge, and institutional responsibility,
among other things.22 Professors Janet L. Dolgin, Catherine Fisher, and
Terri Shapiro describe the results of a survey and a set of subsequent
interviews they carried out in order to reveal and explain public attitudes
toward hESC research.23
The various moral and political perspectives regarding hESC
research that informed the discussion at the March 2008 conference,
Embryonic Stem Cells, Clones, and Genes: Science, Law, Politics, and
Values, and the articles in this symposium issue intimate that the debate
regarding hESC research is part of a comprehensive debate about the
cultural parameters of the social order in the United States. More
specifically, it is part of a widespread discourse about the role of law in
facilitating the benefits afforded by biomedical research while mitigating
detriments to our health, society, and personhood.

21. Samuel Packer, Embryonic Stem Cells, Intellectual Property, and Patents: Ethical
Concerns, 37 HOFSTRA L. REV. 487, 514-15 (2009).

22. Id. at 490-93,497-502.
23. See Janet L. Dolgin et al., Attitudes About Human Embryos, Embryonic Stem Cell
Research, and Related Matters, 37 HOFSTRA L. REv. 319, 352 (2009) (summarizing the results of
the survey questionnaire and interviews).
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